Here are the editors' top picks for the week ended Oct. 13.
Healthcare tax inversions unlikely amid policy uncertainty
With a recent court decision and a Treasury statement, the fate of an Obama-era rule blocking multinationals from tax inversion deals hangs in the balance, and the uncertainty makes it unlikely companies will risk such transactions.
China FDA issues directive to accept overseas clinical trial data for drugs
The directive comes two days after the State Council proposed reforms to speed up drug approvals and encourage innovation, suggestions that largely mirrored what the China Food and Drug Administration said in May.
With competition rising, biopharma looked to focus on core areas in Q3
With major patent expiries and acquisitions in the rearview mirror, the world's biggest biopharma companies are largely expected to report solid third-quarter revenue growth, but stakes are raised for future performance.
Pfizer's potential consumer health sale could revive M&A ambitions
While Pfizer Inc. has made no decisions on the fate of its consumer health business just yet, analysts expect that a sale would clear the way for an acquisition down the road.
Trump halts ACA subsidies for low-income Americans' out-of-pocket costs
The Trump administration will end payments made under the Affordable Care Act that help eligible low- and moderate-income Americans cover their out-of-pocket costs for prescription drugs and doctor visits, the White House confirmed.
Trump's plan to revamp healthcare faces opposition, long road ahead
While President Donald Trump insisted an executive order he signed would provide "great, great" healthcare to "millions and millions" of Americans, several organizations were skeptical and expressed opposition.
Smith & Nephew reportedly being targeted by Elliott, as CEO moves on
Smith & Nephew plc is reportedly being targeted by U.S. activist investor Elliott Management, although any stake-building in the U.K.-based company has yet to breach the 3% mark.
Hargan fast-tracked to top HHS job after slow ride to deputy spot
Just days after being sworn in as the deputy secretary of the U.S. Department of Health and Human Services, Eric Hargan has been catapulted to the agency's top spot, at least in an acting capacity. But his road to the deputy job came much slower.
Spark's gene therapy Luxturna wins FDA panel endorsement
Spark Therapeutics Inc.'s experimental gene therapy Luxturna on Oct. 12 won the unanimous backing of an FDA advisory panel, making the drug's chances for U.S. approval more favorable.
Capitol Checkup: Trump's deal motive; mental health champs honored; FDA/FTC team
President Donald Trump is showing new willingness to work with Democrats on healthcare reform, the pharmaceutical industry will celebrate mental health champions, and consumer protection and drug regulators plan to jointly discuss market competition.
Opioid epidemic needs innovative, bold efforts and more funding, officials say
The U.S. opioid epidemic has gotten worse, not better, and it is going to take bold and innovative efforts, plus millions more of federal dollars, to address it, the nation's top health officials told a Senate panel.